TRUNCATE-TB预设探索性分析:8周方案治疗利福平敏感肺结核的疗效与安全性
TRUNCATE-TB为多臂多阶段开放标签随机对照试验,675例利福平敏感肺结核患者随机接受24周标准治疗或TRUNCATE策略(初始8周治疗后监测、必要时再治疗)。预设探索性分析显示,8周方案不良结局比例高于标准治疗,差异因方案而异;最佳8周方案(贝达喹啉-利奈唑胺)也仅应在包含治疗后监测和必要再治疗的管理策略中使用。
要点
- 8周方案不良结局(主要为复发)比例高于24周标准治疗,差异因方案而异。
核心结论
- 8周方案疗效差于标准治疗,但与标准治疗的差异因方案而异。
- 即使最佳8周方案(贝达喹啉-利奈唑胺)也仅应在包含治疗后监测和必要再治疗的管理策略中使用。
研究设计与样本
- TRUNCATE-TB为多臂、多阶段、开放标签、随机对照试验,纳入18-65岁利福平敏感肺结核患者。
- 参与者随机接受24周标准治疗(利福平、异烟肼、吡嗪酰胺、乙胺丁醇)或TRUNCATE管理策略(初始8周治疗,然后治疗后监测和必要时再治疗)。
- 四种8周方案均含五种药物,改良自标准治疗:高剂量利福平+利奈唑胺、高剂量利福平+氯法齐明、贝达喹啉+利奈唑胺,均联合异烟肼、吡嗪酰胺、乙胺丁醇;以及利福喷丁+利奈唑胺+左氧氟沙星联合异烟肼、吡嗪酰胺。
- 2018年3月21日至2020年3月26日入组675例参与者(意向性治疗人群674例),随机分配至标准治疗组或四种8周方案组之一;两种8周方案进入完全入组。
- 本预设探索性分析在意向性治疗人群中评估8周方案的疗效(不良结局比例及与标准治疗的差异,采用贝叶斯方法)和安全性。
主要发现
- 标准治疗组不良结局(主要为复发)7/181(4%)。
- 3-4级不良事件:标准治疗组24/181(14%),利福平-利奈唑胺方案组20/184(11%),贝达喹啉-利奈唑胺方案组22/189(12%)。
关键数值与推荐
- WHO推荐新药方案治疗利福平敏感结核的最佳疗程为2个月。
临床怎么用
- 8周方案疗效差于标准治疗,差异因方案而异。
- 即使最佳8周方案(贝达喹啉-利奈唑胺)也仅应在包含治疗后监测和必要再治疗的管理策略中使用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: WHO recommends a 2-month optimal duration for new drug regimens for rifampicin-susceptible tuberculosis. We aimed to investigate the efficacy and safety of the 8-week regimens that were assessed as part of the TRUNCATE management strategy of the TRUNCATE-TB trial. METHODS: TRUNCATE-TB was a multi-arm, multi-stage, open-label, randomised controlled trial in which participants aged 18-65 years with rifampicin-susceptible pulmonary tuberculosis were randomly assigned via a web-based system, using permuted blocks, to 24-week standard treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol) or the TRUNCATE management strategy comprising initial 8-week treatment, then post-treatment monitoring and re-treatment where needed. The four 8-week regimens comprised five drugs, modified from standard treatment: high-dose rifampicin and linezolid, or high-dose rifampicin and clofazimine, or bedaquiline and linezolid, all given with isoniazid, pyrazinamide, and ethambutol; and rifapentine, linezolid, and levofloxacin, given with isoniazid and pyrazinamide. Here, we report the efficacy (proportion with unfavourable outcome; and difference from standard treatment, assessed via Bayesian methods) and safety of the 8-week regimens, assessed in the intention-to-treat population. This prespecified exploratory analysis is distinct from the previously reported 96-week outcome of the strategy in which the regimens were deployed. This trial is registered with ClinicalTrials.gov (NCT03474198). FINDINGS: Between March 21, 2018, and March 26, 2020, 675 participants (674 in the intention-to-treat population) were enrolled and randomly assigned to the standard treatment group or one of the four 8-week regimen groups. Two 8-week regimens progressed to full enrolment. An unfavourable outcome (mainly relapse) occurred in seven (4%) of 181 participants on standard treatment; 46 (25%) of 184 on the high-dose rifampicin and linezolid-containing regimen (adjusted difference 21·0%, 95% Bayesian credible interval [BCI] 14·3-28·1); and 26 (14%) of 189 on the bedaquiline and linezolid-containing regimen (adjusted difference 9·3% [4·3-14·9]). Grade 3-4 adverse events occurred in 24 (14%) of 181 participants on standard treatment, 20 (11%) of 184 on the rifampicin-linezolid regimen, and 22 (12%) of 189 on the bedaquiline-linezolid regimen. INTERPRETATION: Efficacy was worse with 8-week regimens, although the difference from standard treatment varied between regimens. Even the best 8-week regimen (bedaquiline-linezolid) should only be used as part of a management strategy involving post-treatment monitoring and re-treatment if necessary. FUNDING: Singapore National Medical Research Council; UK Department of Health and Social Care; UK Foreign, Commonwealth, and Development Office; UK Medical Research Council; Wellcome Trust; and UK Research and Innovation Medical Research Council.
引用
- Paton NI, Cousins C, Sari IP, et al. Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial. Lancet Infect Dis. 2025. PMID: 40414233. doi:10.1016/S1473-3099(25)00151-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。